Later, our and several other groups developed small molecule RAD52 inhibitors to specifically suppress the growth of BRCA-deficient cancer cells (Chandramouly et al., 2015; Hengel et al., 2016; Huang et al., 2016; Sullivan et al., 2016; Hengel et al., 2017; Sullivan-Reed et al., 2018). Here, RAD52 is linked to cancer.